G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

VKORC1

Vitamin K Epoxide Reductase Complex Subunit 1

CHR 16
16p11.2

Overview

The VKORC1 gene encodes the rate-limiting enzyme of the hepatic vitamin K cycle. Without active reduced vitamin K, the liver cannot carboxylate key blood-clotting factors (II, VII, IX, and X) as well as matrix Gla proteins protecting arterial walls from calcification.

VKORC1 is also the direct pharmacological target of oral vitamin K antagonists such as warfarin (Coumadin) and phenprocoumon, making it alongside CYP2C9 one of the most validated dosing markers in coagulation genetics.

📍 Position
16p11.2 (Chromosome 16)
🏷️ Category
Detoxification & Coagulation
🧪 Function
Vitamin K Recycling Enzyme
📊 Influence
Warfarin / coumarin sensitivity

Function of VKORC1

Warfarin inhibits VKORC1 to thin blood selectively. Because the promoter SNP rs9923231 changes how much VKORC1 enzyme liver cells synthesize in the first place, starting doses vary dramatically from person to person.

Key Aspects:

📉 Sensitive Phenotype (-1639 A/A)

Lower baseline VKORC1 levels mean even modest warfarin doses block most of the available enzyme, raising INR rapidly and requiring low initial doses.

📈 Higher Requirement (-1639 G/G)

Full hepatic enzyme production provides greater buffering capacity, generally calling for higher average maintenance doses to stay within target INR.

💡 FDA & CPIC Dosing Algorithms: Combined testing of VKORC1 (-1639G>A) and CYP2C9 (*2/*3) explains up to 40% of inter-individual warfarin dose variation, far exceeding age or body weight alone.

🧬 Genetic Variants (SNPs)

Two regulatory SNPs in VKORC1 explain the majority of inherited coumarin dose variability worldwide:

rs9923231
16:31096368
Standard

G
/
Sensitive

A
Promoter -1639G>A
Reduces promoter transcription activity; A/A carriers typically need ~40-60% lower warfarin maintenance doses than G/G individuals.
A allele frequency:
~40% (Europe), ~90% (East Asia)
rs7294
16:31091000
Reference

G
/
Variant

A
3′-UTR 3730G>A
Marks haplotypes associated with relatively higher coumarin dose requirements and lower bleeding tendency during induction.
A allele frequency:
~35% (Europe)

Practical Significance

✅ Strategies & Guidance

  • INR Monitoring During Initiation: Close INR tracking prevents supratherapeutic over-anticoagulation in the first two weeks.
  • Consistent Vitamin K Intake: Keep daily intake of leafy greens (spinach, kale, broccoli) steady rather than eliminating them completely.
  • Medication Card Documentation: Share known VKORC1 and CYP2C9 genotypes with anticoagulation clinics prior to starting warfarin.

⚠️ Clinical Notes & Risks

  • Major Bleeding Risk: Standard loading doses in A/A or compound VKORC1/CYP2C9 carriers may overshoot target INR quickly.
  • Subtherapeutic Dosing: Abrupt high-dose vitamin K supplements can antagonize therapy acutely.
  • Note on DOACs: Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) act independently of VKORC1.
🩺 Medical Disclaimer: Genetic test results for VKORC1 (Vitamin K Epoxide Reductase Complex Subunit 1) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #608547 (Vitamin K Epoxide Reductase Complex, Subunit 1)
  • dbSNP: rs9923231 (-1639G>A), rs7294
  • CPIC Guideline: Pharmacogenetics-Guided Warfarin Dosing
  • ClinVar: VKORC1 Warfarin Sensitivity Clinical Annotations

Last Update: November 2026

Related Research Guides for VKORC1

Related Genes in Detoxification